News Breaks |
|
|
| October 7, 2012 |
| 13:11 EDT |  | NVS | Novartis CEO says patent end for Diovan to challenge 1H13, SonntagsZeitung says
Novartis (NVS) CEO Joe Jimenez says the patent expiration of Diovan in the U.S. is significant and will create a headwind for the first half of 2013, says SonntagsZeitung. Reference Link |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT |  | NVS | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT |  | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
|
|
|
|
